9 Results for "

mitochondrial complex IV

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "mitochondrial complex IV" in MCE Product Catalog:

Cat. No.: HY-114220
CAS No.: 873546-31-7
Purity:  98.41%
Research Areas:  

Infection

T-2307 is an antifungal agent with blood-brain barrier penetration. T-2307 exhibits broad-spectrum antifungal activity against Candida species, including echinocandin-resistant strains, Cryptococcus neoformans, Cryptococcus gattii, and some Aspergillus species. T-2307 selectively targets fungal mitochondrial respiratory chain complexes III and IV, causing collapse of the fungal mitochondrial membrane potential and exerting fungicidal or fungistatic effects. T-2307 can be used in research related to fungal infections such as invasive candidiasis, cryptococcosis, and aspergillosis .
loading...
    loading...
Cat. No.: HY-118075
CAS No.: 606-06-4
Coenzyme Q2 is a benzoquinone electron carrier in the mitochondrial electron transport chain and a p53-dependent apoptosis inducer. Coenzyme Q2 induces p53 phosphorylation at Ser15, promoting p53 accumulation and functional activation. Coenzyme Q2 induces ROS generation, caspase-3 activation, DNA fragmentation, phosphatidylserine externalization, mitochondrial permeability transition pore opening, and oxidative phosphorylation uncoupling. Coenzyme Q2 inhibits Complex I, Complex III, and Complex IV activities, disrupting electron transport and membrane potential generation. Coenzyme Q2 induces excessive mitochondrial proton leak in forebrain mitochondria. Coenzyme Q2 causes loss of righting reflex in mice, accompanied by slow-wave delta EEG activity and reversible loss of wakefulness. Coenzyme Q2 inhibits lipid peroxidation and scavenges superoxide radicals. Coenzyme Q2 is used in research on leukemia, myocardial ischemia-reperfusion injury, and mitochondrial encephalomyopathy .
loading...
    loading...
Cat. No.: HY-132178B
Research Areas:  

Metabolic Disease

Cytochrome C oxidase (complex IV) (EC 7.1.1.9) is the unique terminal oxidase of the mitochondrial respiratory chain (RC) in mammals. Cytochrome C oxidase is made up of thirteen subunits that catalyze the transfer of electrons from ferro-cytochrome c to molecular oxygen .
loading...
    loading...
Cat. No.: HY-N8693
CAS No.: 362472-81-9
Withanoside IV is an orally active, blood-brain barrier-permeable withanolide derivative. Withanoside IV specifically binds to the Sudlow I site of HSA, induces secondary structural changes in HSA, and forms stable HSA complexes. Withanoside IV inhibits the enzymatic activity of COX-2. Withanoside IV induces axonal regeneration, peripheral nervous system myelination and increased axonal density in spinal cord tissue, reduces reactive gliosis-related changes, and improves hindlimb motor function. Withanoside IV binds to amyloid-β 1-42 to inhibit its aggregation, induces neurite outgrowth and synapse reconstruction, repairs damaged axons and dendrites, enhances mitochondrial biogenesis, exerts neuroprotective effects via the BDNF and SIRT1 signaling pathways, reduces ROS production and neuronal apoptosis, and ameliorates memory deficits. Withanoside IV inhibits the activity of the SARS-CoV-2 main protease. Withanoside IV can be used in research related to spinal cord injury, Alzheimer's disease, and coronavirus disease 2019 (COVID-19) .
loading...
    loading...
Cat. No.: HY-158156
Target:  

NF-κB Apoptosis

Research Areas:  

Cancer

NF-κB-IN-16 (compound 9) is a complex (Pt(IV) complex) of NF-κB inhibitor and Cisplatin (HY-17394), which has high efficacy and low toxicity in anti-tumor activity. active. NF-κB-IN-16 can cause DNA damage, induce mitochondrial dysfunction, produce reactive oxygen species, and induce apoptosis through the mitochondrial pathway and endoplasmic reticulum stress. NF-κB-IN-16 potently inhibits the NF-κB/MAPK signaling pathway and disrupts PI3K/AKT signaling. NF-κB-IN-16 also exhibits excellent in vivo antitumor efficiency and low toxicity in A549 or A549/CDDP xenograft models .
loading...
    loading...
Cat. No.: HY-190512
CAS No.: 3101626-89-2
Copper chelator is a copper chelator with anticancer activity. Copper chelator inhibits mitochondrial complex IV through copper depletion, triggering ROS/RNS stress and activating ERK/JNK/p38/AMPK, while suppressing the NRF2 antioxidant response through Keap1 upregulation. Copper chelator induces paraptosis-like death, endoplasmic reticulum stress, mitochondrial dysfunction, and ATP depletion, and inhibits cancer cell invasion and metastasis by downregulating MMP and FOSL1. Copper chelator chelates Cu (I) to form Cu complexes and releases NO with glutathione. Copper chelator inhibits the proliferation of Cu-sensitive melanoma cells and organoids as well as melanoma tumor growth in mice. Copper chelator can be used for research on melanoma .
loading...
    loading...
Cat. No.: HY-114220A
Research Areas:  

Infection

T-2307 diformate is an antifungal agent with blood-brain barrier penetration. T-2307 diformate exhibits broad-spectrum antifungal activity against Candida species, including echinocandin-resistant strains, Cryptococcus neoformans, Cryptococcus gattii, and some Aspergillus species. T-2307 diformate selectively targets fungal mitochondrial respiratory chain complexes III and IV, causing collapse of the fungal mitochondrial membrane potential and exerting fungicidal or fungistatic effects. T-2307 diformate can be used in research related to fungal infections such as invasive candidiasis, cryptococcosis, and aspergillosis .
loading...
    loading...
Cat. No.: HY-183448
CAS No.: 117666-86-1
ETMTC is an orally active anti-inflammatory and antioxidant agent. ETMTC inhibits IKK-mediated phosphorylation and degradation of IkBα, blocks nuclear translocation and activation of NF-κB, and reduces the expression of ICAM-1, VCAM-1, E-selectin, Th2 cytokines and eosinophil chemokines. ETMTC abrogates neutrophil adhesion to endothelial monolayers and inhibits TNF-α-induced ROS production. ETMTC activates Nrf2, and enhances the activities of mitochondrial complex I and IV. ETMTC reduces lipid peroxidation levels, oxidative DNA damage, cytochrome c and caspase 9 activity, and decreases goblet cell metaplasia and subepithelial fibrosis. ETMTC can be used for the research of inflammatory diseases and asthma .
loading...
    loading...
Cat. No.: HY-182067
Research Areas:  

Cancer

anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer .
loading...
    loading...